Michael Krathen

Back to Profile

Publication Details

  • Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.

    Braunstein I, Goodman NG, Rosenbach M, Okawa J, Shah A, Krathen M, Kovarik CL, Luning Prak E, Werth VP. J Am Acad Dermatol. 2012; 66 (4): 571-82

    Lenalidomide is a thalidomide analogue that may serve as an adjunctive therapy for treatment-refractory cutaneous lupus erythematosus (CLE).

    PubMedID: 21821308

Stanford Medicine Resources:

Footer Links: